BIIB News

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell Congress testimony.

FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing.

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.